brolucizumab

REMS

Neovascular (wet) age-related macular degeneration (AMD).
Diabetic macular edema.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity;
Ocular/periocular infection; Active intraocular inflammation
Lactation: Lactation.

Use Cautiously in:

OB: Use during pregnancy only if potential maternal benefit justifies fetal risk;
Rep: Women of reproductive potential;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: MI

EENT: blurred vision, ↑intraocular pressure (from procedure), ↑lacrimation, cataracts, conjunctival hemorrhage, conjunctivitis, corneal abrasion, endophthalmitis (from procedure), eye pain, intraocular inflammation, punctate keratitis, retinal detachment (from procedure), retinal hemorrhage, retinal tear, retinal vascular occlusion, retinal vasculitis, vitreous detachment, vitreous floaters

Neuro: STROKE

Misc: hypersensitivity reactions

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Solution for injection (in vials and prefilled syringes): 6 mg/0.05 mL

Route/Dosage ⬆ ⬇

Neovascular Age-Related Macular Degeneration

Intravitreal (Adults ): 6 mg every 4 wk for first three doses, then 6 mg every 8–12 wk.

Diabetic Macular Edema

Intravitreal (Adults ): 6 mg every 6 wk for first five doses, then 6 mg every 8–12 wk.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Binds to and inactivates vascular endothelial growth factor (VEGF) receptors which normally promote neovascularization and vascular permeability.

Therapeutic effects:

Slowed progression of AMD.
Improve visual acuity in diabetic macular edema.

Classifications ⬆ ⬇

Therapeutic Classification: ocular agents

Pharmacologic Classification: vascular endothelial growth factor antagonists

Pharmacokinetics ⬆ ⬇

Absorption: Action is local following intravitreal injection, minimal systemic absorption occurs.

Distribution: Distribution occurs mainly in the vitreal space.

Metabolism/Excretion: Degraded by proteolytic enzymes. Undergoes passive renal excretion.

Half-Life: 4.4 days.

Time/Action Profile ⬆ ⬇

(improved visual acuity)

ROUTE	ONSET	PEAK	DURATION
Intravitreal	Within 4 wk	8–12 wk	Maintained throughout treatment

Patient/Family Teaching ⬆ ⬇

Advise patient to notify ophthalmologist immediately if eye becomes red, sensitive to light, painful, or develops a change in vision.
May cause temporary visual disturbances. Caution patient to avoid driving or other activities requiring good eyesight until response to medication is known.
Rep: May cause fetal harm. Advise females of reproductive potential to use highly effective contraception and avoid breastfeeding during and 1 mo after last dose. May impair fertility.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0078- Novartis Pharmaceuticals Corporation
- 0078-0827- BEOVU
  - 0078-0827-60- 1 SYRINGE, GLASS in 1 CARTON (0078-0827-60) / .05 mL in 1 SYRINGE, GLASS

0078- Novartis Pharmaceuticals Corporation
- 0078-0827- BEOVU
  - 0078-0827-98- 1 SYRINGE, GLASS in 1 CARTON (0078-0827-98) / .05 mL in 1 SYRINGE, GLASS

49187- Lonza AG
- 49187-0226-
  - 49187-0226-1- 1000 mL in 1 BOTTLE (49187-0226-1)

section name header

Indications ⬇